Quel est le prix pour CohBar, Inc. (CWBR)

Le prix pour CohBar, Inc. (CWBR) est $0.41

Quelle est la capitalisation boursière pour CohBar, Inc. (CWBR)

La capitalisation boursière pour CohBar, Inc. (CWBR) est $1.08M

Bénéfices de CohBar, Inc. (CWBR)

CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.

Année	Bénéfices	Changez
2026 (TTM)	$-12.69M	4.20%
2022	$-12.18M	-21.33%
2021	$-15.48M	-4.85%
2020	$-16.26M	24.69%
2019	$-13.04M	-16.94%
2018	$-15.71M	59.72%
2017	$-9.83M	61.86%
2016	$-6.08M	56.64%
2015	$-3.88M	113.13%
2014	$-1.82M	108.53%
2013	$-872.64K	-40.68%
2012	$-1.47M	0.00%

Année

Bénéfices

Changez

2026 (TTM)

$-12.69M

4.20%

2022

$-12.18M

-21.33%

2021

$-15.48M

-4.85%

2020

$-16.26M

24.69%

2019

$-13.04M

-16.94%

2018

$-15.71M

59.72%

2017

$-9.83M

61.86%

2016

$-6.08M

56.64%

2015

$-3.88M

113.13%

2014

$-1.82M

108.53%

2013

$-872.64K

-40.68%

2012

$-1.47M

0.00%

Entreprise	Bénéfices	Différence de bénéfices	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-41,678.29%	US
Argenx SE ARGX.US	$1.95B	-15,475.59%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-23,791.93%	BE

Entreprise

Bénéfices

Différence de bénéfices

Pays